Under Armour Inc Class A (UAA) Stock Price Today
Aura AI Summary
Key Stats
- $1.83BMarket Cap
- 12,684,364Volume
- Consumer CyclicalSector
- $8.1452W High
- $4.1752W Low
- 98 DaysTypical Hold Time
- $2.81BEnterprise Value
- -Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Under Armour Inc Class A (UAA) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Under Armour Inc Class A has traded between a low of $4.17 and a high of $8.14, highlighting its annual price range. Buy and sell Under Armour Inc Class A shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Most Recent News
GameStop insiders buy millions in shares, signaling strong confidence despite stock volatility.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...

Stocks fall as uniQure, Fair Isaac, and ClearPoint Neuro lead losses on clinical and regulatory concerns.
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...

Iovance, SoundThinking, and WidePoint stocks surge on revenue upgrades, acquisition deal, and government contract news
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.